Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7237664 | 0.87 | TSHR (0.35) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL7229497 | 0.87 | TSHR (0.35) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL31573806 | 0.82 | TDP1 (0.38) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL26739671 | 0.82 | MMP1 (0.35) | TDP1TSHRLMNAMMP1MMP2 | |
| SCHEMBL11016719 | 0.82 | LMNA (0.40) | TSHRMAPTLMNAMMP1MMP2 | |
| SCHEMBL23249534 | 0.80 | MEN1 (0.37) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL9730563 | 0.80 | MEN1 (0.37) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL12205685 | 0.80 | MEN1 (0.37) | TDP1TSHRMAPTLMNAMMP1 | |
| SCHEMBL4812651 | 0.79 | — | — | |
| SCHEMBL9729964 | 0.78 | MMP1 (0.52) | TDP1MMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287102-A1 | CHAIN EXTENDERS | POLYNOVO BIOMATERIALS PTY LIMITED (AU) | 2011-11-24 | — | — | US | disclosed |
| US-20110287102-A1 | CHAIN EXTENDERS | POLYNOVO BIOMATERIALS PTY LIMITED (AU) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287102-A1 | CHAIN EXTENDERS | UMPS, PUF60, SMCHD1 | TDP1 2133/4885TSHR 4016/4885MAPT 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.